The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease

l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and less than 1% of the oral dose is estimated to reach the brain unchanged. l-Dopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoon, Monique, Petzer, Jacobus P., Viljoen, Francois, Petzer, Anél
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150007/
https://www.ncbi.nlm.nih.gov/pubmed/29186917
http://dx.doi.org/10.3390/molecules22122076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150007/
https://www.ncbi.nlm.nih.gov/pubmed/29186917
http://dx.doi.org/10.3390/molecules22122076

Ejemplares similares